FILTERED RESULTS
FILTERS
Ads Top
DARK MODE
CHART
    Filters
      Symbols
      Sentiment
      Impact
      Search
      FILTERED RESULTS

        

      Upgrade your plan

      Morgan Stanley Increases Price Target for Gilead to $175

      Morgan Stanley has raised its price target for Gilead Sciences, Inc. to $175 from a previous target of $171. The investment firm maintains an Overweight rating on Gilead shares, indicating a positive outlook on the stock's performance.

      This adjustment comes as Morgan Stanley updates its models for the biopharmaceutical sector, taking into account recent IQVIA trends and intra-quarter updates. The changes are made in anticipation of the upcoming Q1 earnings report for the group, reflecting a strategic approach to investment in the biopharma market.

      © 2026 KLEA News. All Rights Reserved. This article is provided for informational purposes only. It is not offered or intended to be used as legal, tax, investment, financial, or other advice.

      Source: KLEA News

      .

      Terra Founder Do Kwon Sentenced to 15 Years in Prison for Fraud